Assessment of treatment response rate to vigabatrin and prednisolone add-on therapy in patients with infantile spasms

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002971

Enrollment

Registered

2018-07-03

Start date

2017-05-01

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : When patients were initially diagnosed with West syndrome, they were first given with vigabatrin. Vigabatrin was first tried with 50 mg/kg/day for 1 day, and was escalated to 100 mg/kg/day. Aft

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were diagnosed with infantile spasms (West syndrome) – who both showed clinical spasms and hypsarrhythmia on EEG.

Exclusion criteria

Exclusion criteria: diagnosis of tuberous sclerosis. on other antiepileptic medications. if their parents or guardians refused to participate in the trial.

Design outcomes

Primary

Measure	Time frame
Cessation of clinical spasms and improvement of EEG (achievement of EEG BASED score of = 2)	—

Secondary

Measure	Time frame
Adverse reactions of vigabatrin and prednisolone	—

Countries

Korea, Republic of

Contacts

Public ContactAra Ko

Yonsei University Health System, Severance Hospital

chereara@gmail.com+82-2-2227-4174

Outcome results